Bioequivalence Binimetinib 3 x 15 mg and 45 mg Formulations

Clinical trial NCT05810740 · COMPLETED

Trial details

NCT number: NCT05810740
Sponsor: Pierre Fabre Medicament
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Melanoma BRAF V600 Mutation Unresectable Melanoma Metastatic Melanoma

Start date: 2022-08-31
Primary completion: 2022-12-22
Enrollment: 37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.